Current Neuro-Oncology
Volume
28 Number 15
31 May 2026
Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 15, 31 May
Jung IH, Yoo J, Choi S, Roh TH, Park HH, Lim J, Moon JH, Kim EH,
Kang SG, Kim SH, Chang JH.
Survival
analysis of adult
midline-located gliomas and diffuse midline gliomas: beyond the
H3K27 mutation paradigm.
J
Neurooncol. 2026 May 22;178(1):17. doi:
10.1007/s11060-026-05625-0. PMID:
42174302˰ ˍ
Rudra Gupta T, Polley MC, Redd R, Lee EQ, Arrillaga-Romany I,
Gilbert MR, Tan Y, Touat M, Drappatz J, Welch MR, Galanis E,
Ahluwalia MS, Colman H, Nabors LB, Hepel J, Elinzano H, Schiff D,
Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR,
Batchelor TT, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL,
Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Aizer A, Doherty
L, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Ligon KL,
Weller M, Mehta MP, Wen PY, Trippa L, Rahman R.
Treatment
Effect Reanalysis of the Randomized Individual Screening Trial of
Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma
With External Control Data.
J
Clin Oncol. 2026 May 22:JCO2501586. doi:
10.1200/JCO-25-01586. PMID:
42172567. Trial
registration ID: NCT02977780˰
ˍ
Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M,
Bommi P, Dixit K, Kumthekar P, Sharp L, Lezon R, Garcia D,
Sonabend AM, McCortney K, Castro BA, Chandler JP, Gondi V, Grimm
SA, Miska JM, Heimberger AB, Dobinda K, Zhang H, Sachdev S, Juhasz
C, James CD, Allen JM, Horbinski C, Lesniak MS, Stupp R,
Wainwright DA.
Phase 1 evaluation of
patients with newly diagnosed glioblastoma treated with radiation,
nivolumab, and IDO1 enzyme inhibitor BMS-986205.
Clin
Cancer Res. 2026 May 26. doi:
10.1158/1078-0432.CCR-26-1124. PMID:
42189896. Trial
registration ID: NCT04047706.
ˍ
Ghaedian T, Aghaei H, Rakhsha A, Ghaedian M, Alipour A, Shariat S,
Shabani Z, Eghbal K, Jamali M, Rahmanian A, Mohammadhosseini E,
Ashrafi Z, Davlatov M.
Diagnostic
accuracy of [99mTc]-Tc-HYNIC-PSMA-11
SPECT/CT in differentiating tumor recurrence from post-treatment
changes in glioblastoma.
Neuroradiology.
2026 May 28. doi:
10.1007/s00234-026-04042-4. PMID:
42207247˰ ˍ
Zabor EC.
Propensity Score-Matched
External Controls in Rare Disease Trials: A Promising Tool
Requiring Rigorous Validation.
J
Clin Oncol. 2026 May 28:JCO2600816. doi:
10.1200/JCO-26-00816. PMID:
42208047. ˍ
Ellingson BM, Cloughesy TF, Ye X, Teraishi A, Raymond C, Oshima S,
Sanvito F, Wen PY, Walbert T, Campian JL, Nabors LB, Ozer BH,
Desai A, Omuro A, Desideri S, Danda N, Grossman SA, Bindra RS,
Schiff D.
Tumor Growth Rate (TGR)
Analysis Predicts Survival in a Multicenter Phase II Study of the
PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent
IDH-Mutant Gliomas (ABTC-1801).
AJNR
Am J Neuroradiol. 2026 May 29:ajnr.A9438. doi:
10.3174/ajnr.A9438. PMID:
42217836. Trial
registrationID: NCT03914742˰
ˍ
Salahi Ardekani O, Zarezade M, Meymandi B, Azami N, Mahdavi B,
Shahani T.
Recent advances in
oncolytic virotherapy: insights from clinical trials and
combination treatment strategies.
Virol
J. 2026 May 29. doi:
10.1186/s12985-026-03207-0. PMID:
42216079. ˍ
Wang D, Liu X, Wang J, Zhang B, Zhai S, Xu J, Wang L, Zheng Y, Wei
W, Zhou Y.
Efficacy of
chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic
pontine glioma: a study based on single-center and SEER data.
J
Neurooncol. 2026 May 30;178(1):36. doi:
10.1007/s11060-026-05622-3. PMID:
42218248. ˍ
Yao J, Nilsen O, Cher L, Gan HK.
Treatment
outcomes and toxicity of carboplatin after relapse in patients
with glioma.
Neurooncol
Pract. 2025 Nov 21;13(3):588-596. doi:
10.1093/nop/npaf120. PMID:
42131760˰ ˍ
Skeie BS, Sleire L, Grüner ER, Bragstad S, Heggdal JI, Eide
GE, Enger PØ.
Phase I trial
combining sulfasalazine and gamma knife radiosurgery for recurrent
glioblastoma.
MethodsX.
2026 Apr 22;16:103915. doi:
10.1016/j.mex.2026.103915. PMID:
42089023. Trial
registration ID: NCT04205357. ˍ
Song JH, Baron J, Perez CC, Ramesh S, Minturn J, Desai KA, Shah
AC, Belasco JM, Cole KA, Fisher MJ, Storm PB, Madsen PM, Kurtz G,
Lustig RA, Hill-Kayser C, LaRiviere MJ.
Feasibility
and Safety of High-Dose Proton Re-Irradiation in Recurrent
Pediatric Central Nervous System Tumors: A Single-Institution
Retrospective Study.
Pediatr
Blood Cancer. 2026 May 4;73(7):e70371. doi:
10.1002/1545-5017.70371. PMID:
42080317. ˍ
Neutel CLG, Overduin CG, van Eijsden P, Rijpma A, Hannink G,
Grutters JPC, Ardon H, Balvers R, Hovinga K, Wagemakers M, de Witt
Hamer P, Robe PA, Rovers MM, Ter Laan M.
Biopsy
with same-session MRI-guided laser interstitial thermal therapy
versus biopsy alone in patients with primary unresectable
glioblastoma: a multicentre randomised controlled trial.
Lancet
Reg Health Eur. 2026 May 7;66:101696. doi:
10.1016/j.lanepe.2026.101696. PMID:
42112495. Trial
registration ID: NCT05318612. ˍ
Detsky JS, Chan AW, Moore-Palhares D, Safavi AH, Perry J, Fat MJL,
Atenafu EG, Das S, Lipsman N, Heyn C, Maralani P, Czarnota GJ,
Ruschin M, Keller B, Lau A, Chen H, Myrehaug SD, Soliman H, Tseng
CL, Sahgal A.
MRI-guided adaptive
radiotherapy for high grade glioma (UNITED): a single-centre,
single-arm, non-inferiority, phase 2 trial.
Lancet
Oncol. 2026 May 14;27(6):729-737. doi:
10.1016/S1470-2045(26)00088-4. PMID:
42134380. Trial
registration ID: NCT04726397˰
ˍ
Giorgia I, Mauro P, Lorenzo A, Federica N, Tamara I, Valerio DR,
Daniele A, Antonio S, Maurizio S, Alessandro F, Alessandro
P.
Subventricular zone involvement and
cortico-spinal tract infiltration as predictors of outcome in
Glioblastomas: a distinct surgical, clinical and prognostic
entity.
J
Clin Neurosci. 2026 May 17;151:112087. doi:
10.1016/j.jocn.2026.112087. PMID:
42143483˰ ˍ
Sener U, Neth B, Galloway T, Hughes H, Caron S, Batty NR, Alden
EC, Stricker NH, Stricker JL, Kizilbash SH, Breen WG, Lehrer E,
Campian J, Uhm J, Ruff MW, D'Andre SD, Burns TC, Haddad TC,
Flickinger LM, Chan K, Mead-Harvey C, Geyer SM.
Protocol
for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote
cognitive assessment battery and wearable device monitoring
platform while assessing the impact of metformin on cognition and
quality of life in patients with history of cranial radiation.
Contemp
Clin Trials Commun. 2026 May 18;51:101648. doi:
10.1016/j.conctc.2026.101648. PMID:
42211793. Trial
registration ID: NCT06377696. ˍ
Hashii Y, Fujisaki H, Terashima K, Goto H, Horibe K, Sugiyama K,
Takahara-Matsubara M, Goto M, Yanagisawa T, Kikuta A, Kawamoto H,
Hashimoto N, Oka Y, Sugiyama H, Hara J.
Phase
1/2 study of a WT1 peptide-dosing emulsion in pediatric patients
with recurrent/refractory diffuse intrinsic pontine glioma,
glioblastoma, or anaplastic astrocytoma.
Eur
J Cancer. 2026 May 19;242:116808. doi:
10.1016/j.ejca.2026.116808. PMID:
42176363. Trial
registration ID: NCT02750891˰
ˍ
van der Weijden CWJ, Jeltema HR, Wagemakers M, Enting RH,
Stormezand G, Kramer MCA, van Dijken BRJ, van der Hoorn A.
Impact
on survival of glioblastoma patient's in relation to the imaging
of the peri-surgical area: a multi-parametric diffusion MRI,
perfusion MRI and [11C]MET PET study.
Br
J Radiol. 2026 May 20:tqag117. doi:
10.1093/bjr/tqag117. PMID:
42162948. ˍ